My favourite part of this announcement is below. CSL saving and improving lives, saving money for medical boards and governments and improving health outcomes. Proud to be a shareholder. Mounting evidence of the reasons for buying VIFOR.
Approval may also benefit the Chinese healthcare system, among others through implementation of a more effective patient blood management (PBM).
PBM is designed to improve surgical and medical patient outcomes by optimally managing and preserving patients’ blood. Proactive identification and treatment of iron deficiency anemia in patients scheduled for elective surgery has been associated with a reduced need for blood transfusion , reduced length of hospital stay, improved patient’s outcomes, and overall healthcare expenditure reduction.
CSL Price at posting:
$300.34 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)